TOPAMAX SPRINKLE
Clinical safety rating: caution
Comprehensive clinical and safety monograph for TOPAMAX SPRINKLE (TOPAMAX SPRINKLE).
Topiramate is a sulfamate-substituted monosaccharide that blocks voltage-gated sodium channels, enhances GABA-A receptor activity, antagonizes AMPA/kainate glutamate receptors, and inhibits carbonic anhydrase (isoenzymes II and IV).
| Metabolism | Hepatic via CYP3A4 isoenzyme (minor), glomerular filtration and tubular reabsorption with 70% excreted unchanged in urine. |
| Excretion | Approximately 70% of a dose is excreted unchanged in the urine; the remainder is metabolized and eliminated via renal and biliary routes. Renal elimination of both parent drug and metabolites accounts for ~80%, with minimal fecal excretion. |
| Half-life | Terminal elimination half-life is approximately 21 hours in adults with normal renal function. This allows for twice-daily dosing. Half-life increases significantly in renal impairment (e.g., 36-46 hours in moderate to severe impairment). |
| Protein binding | Approximately 15-41% bound to plasma proteins, primarily albumin. Binding is concentration-independent over the therapeutic range. |
| Volume of Distribution | Volume of distribution is approximately 0.6-0.8 L/kg, indicating distribution into total body water. This suggests good tissue penetration, including into the central nervous system. |
| Bioavailability | Oral bioavailability is approximately 80% (range 70-90%) for Topamax Sprinkle capsules. Bioavailability is not affected by food, but administration with food may reduce peak concentration but not overall absorption. |
| Onset of Action | Oral: Clinical effects (e.g., seizure reduction, migraine prophylaxis) may be observed within 1-2 weeks of achieving therapeutic doses, but full effect may require several weeks of dose titration. |
| Duration of Action | Duration of action is approximately 12-24 hours with twice-daily dosing, consistent with half-life. Steady-state is reached in about 4-5 days in patients with normal renal function. |
Initial dose: 25-50 mg orally once daily at bedtime for 1 week; then increase by 25-50 mg/day at weekly intervals to recommended maintenance dose of 200-400 mg/day in 2 divided doses.
| Dosage form | CAPSULE |
| Renal impairment | CrCl <70 mL/min: reduce dose by 50%. CrCl <30 mL/min: use 50% of recommended starting dose and titrate slowly. |
| Liver impairment | Child-Pugh Class B: reduce dose by 50%. Child-Pugh Class C: reduce dose by 75%. |
| Pediatric use | Ages 2-16 years: initial 1-3 mg/kg/day (max 25 mg/day) at bedtime; increase by 1-3 mg/kg/day at weekly intervals to maintenance of 5-9 mg/kg/day in 2 divided doses. Max dose 400 mg/day. |
| Geriatric use | Initiate at lower end of dosing range (25 mg/day). Titrate more slowly (every 2 weeks) due to increased sensitivity and reduced renal function. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for TOPAMAX SPRINKLE (TOPAMAX SPRINKLE).
| Breastfeeding | Topiramate is excreted into breast milk with a milk-to-plasma ratio of approximately 0.86. Infant serum concentrations are low (10-20% of maternal levels). No adverse effects reported in breastfed infants, but monitor for sedation, poor feeding, and diarrhea. Use with caution if essential. |
| Teratogenic Risk | Pregnancy Category D. First trimester exposure associated with increased risk of oral clefts (cleft lip/palate), approximately 1-2% absolute risk. Second and third trimester exposure may cause fetal growth restriction, hypospadias, and minor anomalies. Use only if benefit outweighs risk; consider alternative anticonvulsants. |
■ FDA Black Box Warning
None.
| Serious Effects |
["Hypersensitivity to topiramate or any component of the formulation","Recent alcohol use (within 6 hours) due to increased risk of CNS depression","Concomitant use with metformin in patients with metabolic acidosis (increased risk of lactic acidosis)","Pregnancy (causes fetal harm; must enroll in pregnancy registry)","Breastfeeding (use with caution due to potential adverse effects in infants)"]
| Precautions | ["Acute myopia and secondary angle-closure glaucoma","Oligohidrosis and hyperthermia (especially in pediatric patients)","Metabolic acidosis (increased risk with ketogenic diet)","Suicidal behavior and ideation","Cognitive/neuropsychiatric adverse reactions (including speech/language disorders, psychomotor slowing, somnolence/fatigue)","Fetal toxicity (cleft lip/palate) and decreased fetal weight","Kidney stones (due to carbonic anhydrase inhibition)","Monitor serum bicarbonate levels","Dose adjustment required for renal impairment (CrCl <70 mL/min)"] |
Loading safety data…
| Fetal Monitoring | Monitor maternal serum topiramate concentrations periodically (goal 2-5 mcg/mL). Obtain high-resolution fetal ultrasound at 18-20 weeks to screen for anomalies. Monitor fetal growth throughout pregnancy. After delivery, monitor neonate for withdrawal symptoms (irritability, hypertonia, tremors) and hypoglycemia. |
| Fertility Effects | Topiramate may induce oligomenorrhea or amenorrhea and reduce contraceptive efficacy of oral contraceptives containing ethinyl estradiol (dose-dependent). Advise women of childbearing potential to use adequate contraception. In men, no significant impact on fertility reported. |